Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of pneumococcal polysaccharide protein conjugated vaccine and preparation method thereof

A pneumococcal polysaccharide and pneumococcal technology, applied in the field of immunology, can solve the problems of transient immune response, reduced immunogenicity, and low immune effect

Active Publication Date: 2016-04-20
CANSINO BIOLOGICS INC
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore polysaccharide vaccine has following problem: (1) can only produce weak immune response in young animal or infant body, even does not produce immune response, and immune response increases with age; (2) produces the antibody of low affinity; 3) It only produces a short-term immune response, and does not have the immune memory and immune enhancement effect during repeated vaccination; (4) It is easy to produce immune tolerance; (5) Common adjuvants are not easy to play an immune enhancement effect on this antigen
[0010] Although the 13-valent pneumococcal conjugate vaccine has been marketed, the immune effect of several serotypes is lower than that of other serotypes, such as type 3
And with the increase of different serotypes and repeated use of the same carrier protein, the amount of carrier protein increases, but its immunogenicity decreases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pneumococcal polysaccharide protein conjugated vaccine and preparation method thereof
  • A kind of pneumococcal polysaccharide protein conjugated vaccine and preparation method thereof
  • A kind of pneumococcal polysaccharide protein conjugated vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Preparation of a 7F-type capsular polysaccharide and two different carrier protein conjugates

[0050] Dissolve 5g of the lung chain 7F type polysaccharide in 1L of sodium acetate buffer (50mMpH4.5), at room temperature, stir for 20 minutes with a magnetic stirrer with a magnetic sub, in order to fully dissolve the polysaccharide, add 0.2gNaIO 4 , and react overnight at room temperature, so that the adjacent dihydroxyl groups on the polysaccharide are oxidized into aldehyde groups. Perform 20 equal-volume ultrafiltration changes with purified water, and remove the remaining NaIO in the reaction 4 And the small molecules generated in the reaction process were filtered off to obtain an aqueous solution in which the 7F activated polysaccharide with an activation degree of 6.2 was introduced; and the activated polysaccharide could be concentrated and freeze-dried. The molecular size of the activated polysaccharide was determined using a gel filtration chromatogra...

Embodiment 2

[0055] Example 2 Preparation of a type 3 capsular polysaccharide and two different carrier protein conjugates

[0056] Dissolve 2g of lung chain type 3 polysaccharide in 1L of sodium phosphate buffer (50mMpH7.2), stir for 20 minutes with a magnetic stirrer with a magnet at room temperature, to fully dissolve the polysaccharide, add 0.2gNaIO 4 , and react overnight at room temperature, so that the adjacent dihydroxyl groups on the polysaccharide are oxidized into aldehyde groups. Perform 20 equal-volume ultrafiltration changes with purified water, and remove the remaining NaIO in the reaction 4 and the small molecular substances generated during the reaction were filtered off to obtain an aqueous solution in which the type 3 activated polysaccharide with an activation degree of 9.1 was introduced; and the activated polysaccharide was concentrated and freeze-dried. The molecular size of the activated polysaccharide was determined using a gel filtration chromatography column usi...

Embodiment 3

[0062] Example 3 Preparation of a 13-valent pneumococcal polysaccharide-protein conjugate vaccine

[0063]Single-carrier conjugates such as 4, 6B, 9V, 14, 18C, 19F, 23F were prepared according to known methods in the background art, wherein the carrier proteins were all CRM197. According to the method described in Example 1 or 2, prepare 1,3,5,6A, 7F,19A type polysaccharide double carrier conjugates, wherein 1,5,7F type polysaccharide adopts PspA as the second carrier, 3,6A,19A HiD was used as the second vector. The various conjugated products were formulated according to Table 3 below. After mixing these monovalent components, aluminum phosphate adjuvant was added at a final concentration of 0.5 mg / L.

[0064] Table 3 The carrier protein type of various antigens and the final content in the preparation

[0065]

[0066]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a streptococcus pneumonia polysaccharide protein conjugated vaccine and a preparation method therefor. The streptococcus pneumonia polysaccharide protein conjugated vaccine comprises one or multiple immune conjugates coupling streptococcus pneumonia capsular polysaccharide with protein. At least one immune conjugate in the immune conjugates is formed by coupling a single streptococcus pneumonia capsular polysaccharide with two or more protein.

Description

technical field [0001] The invention relates to the field of immunology, in particular to a pneumococcal polysaccharide-protein conjugated vaccine and a preparation method thereof. Background technique [0002] Infections caused by pneumococci (pulmonary chain) are a major cause of morbidity and mortality worldwide. Pneumonia, febrile bacteremia, and meningitis are the most common manifestations of invasive pneumococcal disease, while bacterial spread within the respiratory tract can lead to middle ear infection, sinusitis, or recurrent bronchitis. Noninvasive manifestations are usually less severe but more common than invasive disease. The likelihood of pneumococcal disease flares during influenza is further increased by the spread of antibiotic-resistant infectious diseases and the fact that pneumococcal pneumonia often follows influenza infection. Diseases caused by Streptococcus pneumoniae have become an important public health problem worldwide. Pneumococcus has beco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/385A61K39/116A61K39/09A61K47/48A61P31/04
CPCA61K39/092A61K47/6415A61K47/646A61P31/04
Inventor 朱涛宇学峰邱东旭毛慧华邵忠琦刘正
Owner CANSINO BIOLOGICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com